Somatostatin receptor expression profile as a potential criterion for discrimination between seminoma and non-seminoma testicular tumors.

The expression of five (sst1-sst5) somatostatin (SRIF) receptor mRNAs was compared between normal and tumoral testicular samples diagnosed as either seminoma or non-seminoma. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis indicated that all testicular tissues studied (total of 24) contained sst5 receptor transcripts, whereas the sst2 was absent in all of them. In contrast to the normal tissue samples, both types of tumors (total of 12) did not contain sst4 transcripts.

Evidence for a selective loss of somatostatin receptor subtype expression in male germ cell tumors of seminoma type.

Somatostatin (SRIF) is a potent antiproliferative signal for both normal and tumoral mammalian cells and an alteration in the SRIF receptor expression pattern has been associated with carcinogenesis. In the present study, the relevance of SRIF signaling to human male germ cell tumors was assessed at the receptor level. The expression of five SRIF receptor (sst1-sst5) mRNAs was estimated by RT-PCR and compared between normal and tumoral testes.